JP2024119812A5 - - Google Patents

Download PDF

Info

Publication number
JP2024119812A5
JP2024119812A5 JP2024079079A JP2024079079A JP2024119812A5 JP 2024119812 A5 JP2024119812 A5 JP 2024119812A5 JP 2024079079 A JP2024079079 A JP 2024079079A JP 2024079079 A JP2024079079 A JP 2024079079A JP 2024119812 A5 JP2024119812 A5 JP 2024119812A5
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
compound according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024079079A
Other languages
English (en)
Japanese (ja)
Other versions
JP7659110B2 (ja
JP2024119812A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/012333 external-priority patent/WO2021142006A1/en
Application filed filed Critical
Publication of JP2024119812A publication Critical patent/JP2024119812A/ja
Publication of JP2024119812A5 publication Critical patent/JP2024119812A5/ja
Application granted granted Critical
Publication of JP7659110B2 publication Critical patent/JP7659110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024079079A 2020-01-07 2024-05-15 Sarm1の阻害剤 Active JP7659110B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062958178P 2020-01-07 2020-01-07
US62/958,178 2020-01-07
US202063065736P 2020-08-14 2020-08-14
US63/065,736 2020-08-14
PCT/US2021/012333 WO2021142006A1 (en) 2020-01-07 2021-01-06 Inhibitors of sarm1
JP2022541796A JP7490781B2 (ja) 2020-01-07 2021-01-06 Sarm1の阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022541796A Division JP7490781B2 (ja) 2020-01-07 2021-01-06 Sarm1の阻害剤

Publications (3)

Publication Number Publication Date
JP2024119812A JP2024119812A (ja) 2024-09-03
JP2024119812A5 true JP2024119812A5 (https=) 2025-01-07
JP7659110B2 JP7659110B2 (ja) 2025-04-08

Family

ID=74505335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541796A Active JP7490781B2 (ja) 2020-01-07 2021-01-06 Sarm1の阻害剤
JP2024079079A Active JP7659110B2 (ja) 2020-01-07 2024-05-15 Sarm1の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022541796A Active JP7490781B2 (ja) 2020-01-07 2021-01-06 Sarm1の阻害剤

Country Status (21)

Country Link
US (1) US12331033B2 (https=)
EP (1) EP4087838A1 (https=)
JP (2) JP7490781B2 (https=)
KR (1) KR20220164471A (https=)
CN (1) CN115175900B (https=)
AU (2) AU2021206651B2 (https=)
BR (1) BR112022013388A2 (https=)
CA (1) CA3163265A1 (https=)
CL (1) CL2022001825A1 (https=)
CO (1) CO2022009514A2 (https=)
CR (1) CR20220375A (https=)
DO (1) DOP2022000141A (https=)
EC (1) ECSP22053394A (https=)
IL (1) IL294507A (https=)
JO (1) JOP20220167A1 (https=)
MX (1) MX2022008395A (https=)
MY (1) MY206478A (https=)
PE (1) PE20230165A1 (https=)
TW (1) TW202140437A (https=)
UA (1) UA128949C2 (https=)
WO (1) WO2021142006A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
CN115916764B (zh) 2020-04-09 2024-09-20 达萨玛治疗公司 作为sarm1抑制剂的吲唑衍生物
US12606558B2 (en) 2020-04-09 2026-04-21 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of SARM1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Sarm1之抑制劑
CN116438171A (zh) * 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
MX2024001322A (es) 2021-07-28 2024-04-30 Nura Bio Inc Derivados de piridina sustituida como inhibidores de sarm1.
JP2023030679A (ja) * 2021-08-23 2023-03-08 国立大学法人 岡山大学 化合物、神経系疾患の予防又は治療薬
EP4634156A1 (en) * 2022-12-15 2025-10-22 Sironax Ltd Sarm1 modulators, preparations, and uses thereof
WO2024158775A1 (en) 2023-01-24 2024-08-02 Disarm Therapeutics, Inc. Pyridazines as sarm1 inhibitors
JP2026503618A (ja) 2023-01-24 2026-01-29 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤としての置換された1h-ピラゾール-4-カルボキサミド
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Hpd抑制劑組成物及使用方法
GB202408068D0 (en) 2024-06-06 2024-07-24 Univ London Treatment of cancer of the central nervous system
CN118593490B (zh) * 2024-06-28 2024-11-19 华中农业大学 Ml216在制备抗猪德尔塔冠状病毒药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
CN1732164A (zh) * 2002-10-30 2006-02-08 沃泰克斯药物股份有限公司 可用作rock及其他蛋白质激酶抑制剂的组合物
US7361669B2 (en) * 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7531556B2 (en) * 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
ZA200704971B (en) * 2004-12-16 2008-09-25 Vertex Pharma Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
CA2591413A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
EP2036905B1 (en) * 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
BRPI0717097A2 (pt) * 2006-09-21 2013-11-26 Novartis Ag Derivados de pirrol úteis para o tratamento de doenças mediadas por citocina
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
EP2238134A2 (en) * 2007-12-20 2010-10-13 Novartis AG Bis-thiazole derivatives, process for their preparation and their use as medicaments
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010093849A2 (en) * 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
RU2570907C2 (ru) * 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
WO2015112847A1 (en) * 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Arylpyridinone itk inhibitors for treating inflammation and cancer
HK1248070A1 (zh) * 2015-05-18 2018-10-12 转化药物开发有限责任公司 作为激酶抑制剂的杂环化合物
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
UY37512A (es) * 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
JP7481329B2 (ja) * 2018-06-07 2024-05-10 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CN111253333A (zh) * 2018-11-30 2020-06-09 青岛清原化合物有限公司 N-(1,3,4-噁二唑-2-基)芳基甲酰胺类或其盐、制备方法、除草组合物和应用
WO2020132045A1 (en) * 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
CA3141404A1 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN115916764B (zh) * 2020-04-09 2024-09-20 达萨玛治疗公司 作为sarm1抑制剂的吲唑衍生物
EP4192828A1 (en) * 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN116438171A (zh) * 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物

Similar Documents

Publication Publication Date Title
JP2024119812A5 (https=)
JPWO2022177917A5 (https=)
JPWO2019195124A5 (https=)
JPWO2020117759A5 (https=)
JPWO2021108628A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2020533352A5 (https=)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2019517587A5 (https=)
CZ20032266A3 (cs) Dávkovací formy pro ošetřování nádorů
JP2017506257A5 (https=)
JPWO2020118060A5 (https=)
JP2005517677A5 (https=)
HUP0203121A2 (hu) Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása
JP5113323B2 (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
JP2019524888A5 (https=)
JP2020534266A5 (https=)
JPWO2019169065A5 (https=)
JPWO2021093839A5 (https=)
JP2018525447A5 (https=)
CN113439080A (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
JP2023011549A5 (https=)
CA2620065A1 (en) Methods and formulations for modulating lyn kinase activity and treating related disorders
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JPWO2020163268A5 (https=)